Compare LOPE & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOPE | RNA |
|---|---|---|
| Founded | 1949 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.0B |
| IPO Year | 2008 | 2020 |
| Metric | LOPE | RNA |
|---|---|---|
| Price | $165.92 | $72.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 20 |
| Target Price | ★ $220.00 | $69.26 |
| AVG Volume (30 Days) | 436.1K | ★ 2.6M |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.46 | N/A |
| Revenue | ★ $1,090,524,000.00 | $20,868,000.00 |
| Revenue This Year | $9.20 | $64.11 |
| Revenue Next Year | $6.83 | $37.25 |
| P/E Ratio | $22.24 | ★ N/A |
| Revenue Growth | 7.05 | ★ 106.27 |
| 52 Week Low | $149.83 | $21.51 |
| 52 Week High | $223.04 | $72.61 |
| Indicator | LOPE | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 77.11 |
| Support Level | $158.98 | $71.18 |
| Resistance Level | $158.67 | $71.79 |
| Average True Range (ATR) | 4.43 | 0.31 |
| MACD | 2.84 | -0.42 |
| Stochastic Oscillator | 92.47 | 82.89 |
Grand Canyon Education Inc is a publicly traded education services company dedicated to serving colleges and universities. GCE's university partner is Grand Canyon University, an Arizona non-profit corporation that operates a comprehensive regionally accredited university that offers graduate and undergraduate degree programs, emphases, and certificates across nine colleges both online, on the ground at its campus in Phoenix, Arizona and at four off-site classroom and laboratory sites. The Company generates all of its revenue through services agreements with its university partners.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.